Astrazeneca (AZNCF) Notes Payables (2016 - 2025)
Historic Notes Payables for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to -$13.0 million.
- Astrazeneca's Notes Payables rose 7796.61% to -$13.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$13.0 million, marking a year-over-year increase of 7796.61%. This contributed to the annual value of -$13.0 million for FY2025, which is 7796.61% up from last year.
- Astrazeneca's Notes Payables amounted to -$13.0 million in Q4 2025, which was up 7796.61% from -$63.0 million recorded in Q3 2025.
- In the past 5 years, Astrazeneca's Notes Payables ranged from a high of -$13.0 million in Q4 2025 and a low of -$980.0 million during Q1 2024
- For the 5-year period, Astrazeneca's Notes Payables averaged around -$308.0 million, with its median value being -$252.0 million (2023).
- Its Notes Payables has fluctuated over the past 5 years, first tumbled by 122432.43% in 2024, then surged by 8912.13% in 2025.
- Astrazeneca's Notes Payables (Quarter) stood at -$291.0 million in 2021, then soared by 37.11% to -$183.0 million in 2022, then fell by 10.93% to -$203.0 million in 2023, then soared by 70.94% to -$59.0 million in 2024, then skyrocketed by 77.97% to -$13.0 million in 2025.
- Its last three reported values are -$13.0 million in Q4 2025, -$63.0 million for Q3 2025, and -$26.0 million during Q2 2025.